Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02389244
Recruitment Status : Recruiting
First Posted : March 17, 2015
Last Update Posted : April 2, 2021
Sponsor:
Information provided by (Responsible Party):
UNICANCER

Tracking Information
First Submitted Date  ICMJE February 9, 2015
First Posted Date  ICMJE March 17, 2015
Last Update Posted Date April 2, 2021
Actual Study Start Date  ICMJE September 2014
Estimated Primary Completion Date September 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 4, 2020)
Non-progression rate [ Time Frame: 8 weeks for cohorts A, B and E, 12 weeks for cohort C, 6 months for cohort D ]
Proportion of patients without disease progression at the defined timepoint after central radiological review (using RECIST 1.1)
Original Primary Outcome Measures  ICMJE
 (submitted: March 16, 2015)
The primary efficacy endpoint is PFS [defined using RECIST 1.1] after central radiological review [ Time Frame: expected average duration of 3 months ]
from the date of randomization until the date of radiological progression or death whatever the cause
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 4, 2020)
  • Progression Free Survival [ Time Frame: expected average duration of 3 months ]
    from the date of randomization until the date of radiological progression or death whatever the cause (if death occurs before progression)
  • Objective response rate [ Time Frame: 6 months ]
    complete response (CR) or partial response (PR) according to RECIST 2009, version 1.1, for all cohorts, and CHOI criteria for chordoma
  • Disease control rate at 6 months [ Time Frame: 6 months ]
    from the date of randomization until the date of death due to any cause
  • Overall survival [ Time Frame: 2 years ]
    from the date of randomization until the date of death due to any cause
  • Duration of response [ Time Frame: expected average duration of 6 months ]
    objective response of CR or PR, whichever is noted earlier, to first disease progression or death before progression
  • Progression-free rate at 3 and 6 months [ Time Frame: at 3 and 6 months ]
    the proportion of patients without progression at 3 and 6 months post randomization
  • Time to progression [ Time Frame: from date of randomization until the date of first observation of progression (up to 6 months) ]
    from date of randomization until the date of first observation of progression
  • Growth Modulation Index defined as ratio of time to progressive disease (PD) under regorafenib to time to progression (TTP) under previous treatment [ Time Frame: expected average duration of 3 months ]
    ratio of time to PD under regorafenib to TTP under previous treatment
  • Toxicity according to NCI-CTCAE V4-0 [ Time Frame: expected average duration of 6 months ]
    according to NCI-CTCAE V4-0 (National Cancer Institut Common Terminology Criteria for Adverse Events)
  • Pain assessment using Visual analog scale (VAS), DN4 scale (Neuropathic Pain Diagnostic Questionnaire) and NPSI scale (Neuropathic Pain Symptom Inventory) [ Time Frame: expected average duration of 6 months ]
    for chordomas cohort only
  • PFS [ Time Frame: from date of randomization until the date of first observation of progression (up to 6 months) ]
    Progression Free Survival according to Choi criteria for Chordoma
Original Secondary Outcome Measures  ICMJE
 (submitted: March 16, 2015)
  • Objective response rate [ Time Frame: 6 months ]
  • Disease control rate at 6 months [ Time Frame: 6 months ]
    from the date of randomization until the date of death due to any cause
  • Overall survival [ Time Frame: the time from the date of randomization until the date of death due to any cause (up to 6 months) ]
  • Duration of response [ Time Frame: expected average duration of 6 months ]
    objective response of CR or PR, whichever is noted earlier, to first disease progression or death before progression
  • Progression-free rate at 3 and 6 months [ Time Frame: at 3 and 6 months ]
  • Time to progression [ Time Frame: from date of randomization until the date of first observation of progression (up to 6 months) ]
  • Growth Modulation Index defined as ratio of time to PD under regorafenib to TTP under previous treatment [ Time Frame: time to PD under regorafenib to TTP under previous treatment (up to 6 months) ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Official Title  ICMJE A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Brief Summary

INDICATION:

Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas and chordomas and either bone or soft tissue metastatic CIC-rearranged sarcomas

Detailed Description

METHODOLOGY:

Randomized, placebo-controlled, multicentric, phase II study -This is a double-blind placebo-controlled trial, with 5 cohorts: cohort A: Osteosarcoma, cohort B: Ewing sarcoma, cohort C: Chondrosarcoma, cohort D : chondroma, cohort E: CIC-rearranged sarcoma. Cohort A, B and C will involve a total of 36 patients (24 Regorafenib + 12 placebo), cohort D a total of 24 evaluable patients (16 Regorafenib + 8 placebo) and cohort E will involve a total of 27 evaluable patients (18 Regorafenib + 9 placebo).

159 patients who meet the eligibility criteria will be randomly assigned in a 2:1 ratio to the following treatment groups :

The Arm A:

Regorafenib (160 mg/d) once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .

Patients receiving regorafenib who experience disease progression and for whom in the investigator opinion, treatment with regorafenib is providing clinical benefit, may continue the treatment following consultation with the study coordinator and the sponsor.

The Arm B:

Placebo plus BSC until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.

Patients will be stratified at randomization according to histology .

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Ewing Sarcomas
  • Chondrosarcomas
  • Osteosarcomas
  • Chondroma
  • CIC-Rearranged Sarcoma
Intervention  ICMJE
  • Drug: Regorafenib
    For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
    Other Name: Stivarga
  • Drug: Placebo
    For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
    Other Name: Placebo tablet
Study Arms  ICMJE
  • Experimental: Regorafenib

    For adult patients (≥18 years old) : 160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .

    For children Age ≥10 years to <18 years old and BSA ≥1.30 m², regorafenib (82 mg/m²) once daily for the 3 weeks on/1 week off (without exceeding 160 mg/day) plus Best Supportive care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent.

    Intervention: Drug: Regorafenib
  • Placebo Comparator: placebo
    Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.
    Intervention: Drug: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 21, 2016)
132
Original Estimated Enrollment  ICMJE
 (submitted: March 16, 2015)
108
Estimated Study Completion Date  ICMJE March 2023
Estimated Primary Completion Date September 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients must have histologically confirmed diagnosis of bone sarcoma (osteosarcoma, Ewing sarcoma of bone, chondrosarcoma or chordoma);
  2. Patients with confirmed disease progression at study entry;
  3. Metastatic disease not amenable to surgical resection or radiation with curative intent;
  4. Patients must have measurable disease;
  5. Prior treatment :

    at least one, but no more than two prior chemotherapy regimen for metastatic disease for osteosarcoma, chondrosarcoma and Ewing sarcoma; neo-adjuvant /maintenance therapy are not counted towards this requirement. Chordoma not pretreated or with 1 or 2 prior (combination) chemotherapy regimen or with one or two prior molecularly targeted therapy, but no more than 2 prior lines of treatment (whatever the indication) can be included. At least 4 weeks since last chemotherapy (6 weeks in case of nitrosoureas and mitomycin C), immunotherapy or any other pharmacological treatment and/or radiotherapy;

  6. Age ≥10 years for osteosarcomas, Ewing sarcomas and chondrosarcomas (for chordomas, patients must be ≥18 years);
  7. Body Surface Area ≥1.30 m²;
  8. Life expectancy of greater than 3 months;
  9. Eastern Cooperative Oncology Group (ECOG) performance status <2 (Karnofsky ≥60%) for adults patients;
  10. Karnofsky scale ≥ 60% for children aged >12 years old / Lansky scale ≥60% for children aged ≤12 years old;
  11. Patients must have adequate bone marrow, renal, and hepatic function, as evidenced by the following within 7 days of study treatment initiation: normal organ function as defined below:

    • Absolute neutrophil count ≥1.5 Giga/L
    • Platelets ≥100 Giga/L
    • Hemoglobin ≥9 g/dL
    • Serum creatinin ≤1.5 x upper limit of normal (ULN)
    • Glomerular filtration rate (GFR) ≥30 ml/min/1.73 m² according to the modified Diet in Renal Disease (MDRD) abbreviated formula
    • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 x ULN
    • Bilirubin ≤1.5 X ULN
    • Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN in patient with liver involvement of their cancer). If Alkaline phosphatase >2.5 ULN, hepatic isoenzymes 5-nucleotidase or gamma-glutamyl transferase (GGT) tests must be performed; hepatic isoenzymes 5-nucleotidase must be within the normal range and/or GGT <1.5 x ULN;
    • lipase ≤1.5 x ULN;
    • Spot urine must not show 1+ or more protein in urine or the patient will require a repeat urine analysis. If repeat urinalysis shows 1+ protein or more, a 24-hour urine collection will be required and must show total protein excretion <1000 mg/24 hours
  12. International Normalized Ratio(INR)/ Partial Thromboplastin Time (PTT) ≤1.5 x ULN;
  13. Recovery to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug/procedure related toxicity (except alopecia, anemia, and hypothyroidism);
  14. Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy;
  15. Women of childbearing potential must have a negative serum β-HCG pregnancy test within 7 days prior randomization and/or urine pregnancy test within 48 hours before the first administration of the study treatment;
  16. Signed informed consent form by adult patients and/or patients parents/legal representatives (if age <18 years) and age appropriate assent form by the patients' parents/legal representatives obtained before any study specific procedure is conducted;
  17. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures;
  18. Patients or parents/legal representatives affiliated to the Social Security System.

Exclusion Criteria:

  1. Prior treatment with any VEGFR inhibitor;
  2. Soft tissue sarcoma;
  3. Other cancer (different histology) within 5 years prior to randomization;
  4. Major surgical procedure, open biopsy, significant trauma, within the last 28 days before randomization;
  5. Cardiovascular dysfunction:

    • Left ventricular ejection fraction (LVEF) <50%
    • Congestive heart failure (New York Heart Association [NYHA]) ≥2
    • Myocardial infarction <6 months before study
    • Cardiac arrhythmias requiring therapy
    • Uncontrolled hypertension
    • Unstable angina or new-onset angina
  6. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within the last 6 months before randomization;
  7. Severe hepatic impairment (Child-Pugh C);
  8. Ongoing infection > Grade 2 according to NCI-CTCAE v4.0;
  9. Known history of human immunodeficiency virus (HIV) infection;
  10. Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy;
  11. Difficulties with swallowing study tablets;
  12. Prior anticancer therapy, including radiotherapy, endocrine therapy, immunotherapy, chemotherapy (CT) within the last 4 weeks (6 weeks for nitrosoureas and mitomycin C), or other investigational agents ; Concomitant antalgic palliative radiotherapy allowed;
  13. Concurrent enrolment in another clinical trial in which investigational therapies are administered;
  14. Known hypersensitivity to the active substance or to any of the excipients;
  15. Pregnant women, women who are likely to become pregnant or are breast-feeding;
  16. For adult patients, individual deprived of liberty or placed under the authority of a tutor;
  17. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
  18. Patients with history of non compliance to medical regimens or unwilling or unable to comply with the protocol;
  19. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent;
  20. Non-healing wound, non-healing ulcer, or non-healing bone fracture;
  21. Patients with evidence or history of any bleeding diathesis, irrespective of severity;
  22. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication;
  23. Use of biological response modifiers, such as granulocyte colony stimulating factor (G-CSF), within 3 weeks of study entry.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 10 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Sabrina YARA 33 (0)85343661 s-yara@unicancer.fr
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02389244
Other Study ID Numbers  ICMJE UC-0150/1309
2013-003910-42 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: no individual participant data is shared
Responsible Party UNICANCER
Study Sponsor  ICMJE UNICANCER
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Florence DUFFAUD, MD PhD La Timone University Hospital
PRS Account UNICANCER
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP